Chaz and others--since the standard of care in the USA is heparin lock and CRMD had to apply for approval as a drug (not a medical device) we should stand a great chance of success in the USA--- i suspect not so much in other countries/Europe/etc----Canada for example already has several lock solutions (some with some of our ingredients) --here's some articles that may interest some new investors here--- the key is no other antimicrobial/anti-fungal catheter lock solution is approved in the USA and IF (that's a big if) the FDA requires any new ones to be classed as a drug they will go thru the same torture we have been thru... just don't think this Defencath will have great success worldwide---the competition will be great and the pricing will be low when more products get approved -- i still like the fact our product has little to no biofilm development and is also anti-fungal--another plus would be so far no resistance has developed --problems with systemic toxicity is a concern as not only do we have to worry about the product getting into the blood stream but also the skill of the nurse/technician putting it into the lock and removing it from the lock.. i suspect this is why CRMD chose this procedure rather than just flusing into the patient.. all of this is JMHO

the first video is an example from canada (interesting video)...
https://stevens.ca/product/kitelocktm-catheter-lock-solution-box-of-60--065-SC001
another one from canada ---
https://iv-therapy.net/topic/new-catheter-lock-solution
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165181/
https://pubmed.ncbi.nlm.nih.gov/24100219/